Top

Archives of Gynecology and Obstetrics

Published in:

01-11-2019 | Breast Cancer | Gynecologic Oncology

The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?

Authors: Jianbin Guo, Ying Zhang, Haili Qian, Fei Ma, Xiujuan Cui, Hua Duan

Published in: Archives of Gynecology and Obstetrics | Issue 5/2019

Abstract

Objective

To evaluate the clinical and pathological features of endometrial cancer (EC) following breast cancer and to assess the effect of the breast cancer hormone receptor status on subsequent EC.

Materials

A retrospective study based on SEER data of EC patients with a history of breast cancer.

Results

A total of 2142 cases met the inclusion criteria. Compared to that of the general population, the incidence of EC following estrogen receptor-positive (ER+) breast cancer and hormone receptor-negative (HR−) breast cancer increased by approximately 16-fold and 15-fold, respectively. Histologically, the proportions of type II EC following ER+ breast cancer, HR− breast cancer and primary EC were 39.6%, 39.4% and 31.2%, respectively (P < 0.001). The proportions of G3 ECs were 26.9%, 28.2% and 19.8%, respectively (P < 0.001). The proportion of patients who died from miscellaneous malignant tumors among EC patients following breast cancer was significantly higher than the proportion of patients among primary ECs. The overall survival rate was worse for EC patients with a history of breast cancer (P < 0.001). There were no significant differences between patients with EC following ER+ breast cancer and those with EC following HR− breast cancer with regard to stage, lymphatic metastasis, outcome or cause of death.

Conclusions

Compared to the general population, the incidence of EC in patients with breast cancer was increased markedly. Patients with EC following ER+ or HR− breast cancer shared the same clinicopathological features and prognoses. All patients need close monitoring regardless of breast cancer hormone receptor status.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef

Ghoncheh Mahshid, Pournamdar Zahra, Salehiniya Hamid (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17(S3):43–46CrossRef

Early Breast Cancer Trialists Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319(26):1681–1692CrossRef

Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N Engl J Med 320(8):479–484CrossRef

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN et al (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629CrossRef

Nagykálnai T, Landherr L, Mészáros E (2011) Aromatase inhibitors and arthralgia. Magy Onkol 55(1):32–39PubMed

Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A et al (2015) Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 101(5):469–473CrossRef

Rieck GC, Freites ON, Williams S (2005) Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol 25(1):39–41CrossRef

Neri F, Maggino T (2009) Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol 30(4):357–360PubMed

10.

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 110(4):354–361CrossRef

11.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122–137CrossRef

12.

Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS et al (2018) Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg 105(9):1098–1106CrossRef

13.

Romagnolo AP, Romagnolo DF, Selmin OI (2015) BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem 15(1):4–14CrossRef

14.

Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L (2018) Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer (Dove Med Press) 10:101–112

15.

Ngeow J, Sesock K, Eng C (2017) Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 165(1):1–8CrossRef

16.

Suba Z (2015) DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers. Drug Des Devel Ther 9:2663–2675CrossRef

17.

MacLachlan TK, Takimoto R, El-Deiry WS (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 22:4280–4292CrossRef

18.

Bulsa M, Urasińska E (2017) Triple negative endometrial cancer. Ginekol Pol 88(4):212–214CrossRef

19.

Jeffy BD, Hockings JK, Kemp MQ, Morgan SS, Hager JA, Beliakoff J et al (2005) An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 7(9):873–882CrossRef

20.

Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA, Lee SW (2000) Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol 20:7450–7459CrossRef

21.

Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA et al (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2(11):1434–1440CrossRef

22.

Liang SX, Pearl M, Liang S, Xiang L, Jia L, Yang B et al (2011) Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer 128(4):763–770CrossRef

23.

Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A et al (2009) Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 112(1):150–154CrossRef

24.

Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH (2004) Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104:255–260CrossRef

25.

Le Donne M, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O (2013) Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett 5(4):1305–1310CrossRef

26.

O'Neill S, O'Driscoll L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16(1):1–12CrossRef

27.

Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRef

28.

Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 81 years median follow-up. Lancet Oncol 12:1101–1108CrossRef

29.

Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:8–30CrossRef

30.

National Comprehensive Cancer Network (NCCN) (2015) Clinical Practice Guidelines in Oncology. Breast Cancer, Version 3. [DB/OL]. http://www.nccn.org

Title: The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?
Authors: Jianbin Guo
Ying Zhang
Haili Qian
Fei Ma
Xiujuan Cui
Hua Duan
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Endometrial Cancer
Endometrial Cancer
Tamoxifen
Published in: Archives of Gynecology and Obstetrics / Issue 5/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05318-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?

Abstract

Objective

Materials

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Offspring of women following bariatric surgery and those of patients with obesity are at an increased risk for long-term pediatric endocrine morbidity

Indications for genetic testing leading to termination of pregnancy

Prophylactic abdominal aortic balloon occlusion in patients with pernicious placenta previa during cesarean section: a systematic review and meta-analysis from randomized controlled trials

Maternal morbidity following caesarean deliveries with barbed suture for uterine closure

Comparison of pelvic floor muscle training isolated and associated with weight loss: a randomized controlled trial

Auricular acupuncture as effective pain relief after episiotomy: a randomized controlled pilot study